Full-Time

Operational Excellence Leader

R&D

Deadline 9/4/26
Sanofi

Sanofi

10,001+ employees

Global pharma company; vaccines and R&D

Compensation Overview

$161.3k - $232.9k/yr

Morristown, NJ, USA

In Person

Bachelor's, Master's

Category
Business & Strategy (1)
Required Skills
Power BI
Six Sigma
Data Visualization
Financial analysis
Data Analysis
Excel/Numbers/Sheets

Get referred to Sanofi

See people who can refer or advise you

Requirements
  • At least 10 years of experience in operational excellence consulting, internal consulting, or advisory roles, preferably within a pharmaceutical or biotechnology research and development environment.
  • A proven track record of managing multiple stakeholder engagements simultaneously and delivering measurable results.
  • Demonstrated success leading end-to-end projects from diagnosis through implementation and value realization.
  • Strong exposure to change management methodologies, stakeholder engagement strategies, and digital transformation initiatives.
  • Deep understanding of pharmaceutical research and development operations, regulatory environments, and industry best practices.
  • A client-focused consulting approach with strong business acumen and the ability to balance strategic thinking with pragmatic execution.
  • The ability to build trusted-advisor relationships, influence without authority in matrix organizations, and navigate complex political landscapes.
  • A high degree of flexibility to work across multiple projects, adjust to changing priorities, and thrive in ambiguous environments.
  • The capacity to drive initiatives and decision-making, shape vision, challenge the status quo with innovation and pragmatism, and inspire trust.
  • Strong mentoring abilities with the capacity to develop people, provide structured feedback, and build organizational capability.
  • A self-directed approach with the ability to take calculated risks, anticipate potential issues, and drive results with minimal supervision.
  • Deep knowledge of Lean, Six Sigma, and other process-improvement methodologies, including FIT4Future, with the ability to select and adapt approaches based on client context.
  • Excellent understanding of research and development processes, value chains, and operational dynamics.
  • Superior analytical and problem-solving skills with the ability to synthesize complex data into actionable insights.
  • Solid financial-analysis and management-accounting knowledge to quantify business cases and demonstrate return on investment.
  • Proven ability to design tailored solutions that address root causes and deliver sustainable impact.
  • A Bachelor's degree is required.
  • Fluent English.
  • The ability to operate with independence, executive maturity, and strong analytical rigor while balancing objective challenges with collaborative partnership.
Responsibilities
  • Facilitate cross-functional workshops with research and development functions and stakeholders to map, streamline, and standardize processes in alignment with strategic priorities.
  • Develop comprehensive project plans, deliverables, and success metrics for each consulting engagement.
  • Design and implement change-management strategies that ensure stakeholder buy-in and sustainable adoption.
  • Provide expert guidance on digital and artificial-intelligence solution selection, deployment, and optimization to maximize value realization.
  • Communicate effectively across all organizational levels by translating complex concepts into actionable insights for diverse audiences.
  • Facilitate alignment of improvement initiatives with research and development strategic priorities through structured stakeholder engagement.
  • Present findings, recommendations, and progress updates to senior leadership and steering committees.
  • Navigate matrix organizations to influence decision-making and drive consensus among diverse stakeholder groups.
  • Develop and track key performance indicators to measure operational efficiency and demonstrate consulting impact.
  • Monitor engagement progress, proactively identify and remove roadblocks, and challenge teams to achieve breakthrough results.
  • Conduct post-implementation reviews to validate value delivery and identify continuous-improvement opportunities.
  • Document lessons learned and best practices to enhance consulting methodologies and organizational knowledge.
  • Coach and mentor research and development staff on Lean methodologies, process-improvement techniques, and change-management best practices.
  • Design and deliver training programs that build internal capability and reinforce sustainable change.
  • Develop and continuously optimize standards, playbooks, and toolkits based on engagement insights and client feedback.
  • Foster a culture of continuous improvement through knowledge sharing and capability development.
Desired Qualifications
  • Familiarity with R&D processes and regulatory requirements in the pharmaceutical industry.
  • Proficiency in data analysis and visualization tools such as Power BI and advanced Excel.
  • Certification in Lean Six Sigma at the Green Belt or Black Belt level.
  • Experience with digital transformation and artificial intelligence or automation solution deployment.

Sanofi is a global pharmaceutical and biotechnology company that develops, manufactures, and sells prescription medicines, over-the-counter products, and vaccines. Its products span immunology, oncology, rare diseases, and vaccines, addressing unmet medical needs through a strong focus on research and development. Sanofi's core product model relies on large-scale R&D, strategic partnerships, and licensing to bring new therapies to markets, with revenue generated from product sales and collaborations. The company differentiates itself by leveraging its global reach, diverse portfolio, and emphasis on patient-centric solutions, safety, and quality to navigate regulatory environments in developed and emerging markets. The company’s goal is to improve health outcomes and quality of life for people worldwide by delivering innovative treatments and vaccines that meet unmet medical needs.

Company Size

10,001+

Company Stage

IPO

Headquarters

Paris, France

Founded

1973

Get referred to Sanofi

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • July 30, 2026: Sanofi raised 2026 sales guidance to about 10% constant-currency growth.
  • July 30, 2026: Dupixent grew 37.6%; launches rose 48.3%, led by Ayvakit and Sarclisa.
  • June 23, 2026: Wayrilz and Cenrifki approvals expanded Sanofi’s rare-disease and multiple-sclerosis franchises.

What critics are saying

  • June 26, 2026: European Commission probed Sanofi for anti-competitive flu-vaccine disparagement in Germany and France.
  • January 2026: FDA rejected tolebrutinib over severe liver injury, blocking Sanofi’s neurology comeback.
  • July 15, 2026: Sanofi sued Pfizer and Moderna, inviting countersuits and expensive patent warfare.

What makes Sanofi unique

  • August 2026: Dupixent topped €5.1 billion quarterly sales, proving platform scale.
  • July 10, 2026: Sarclisa Escena became first anticancer therapy delivered via on-body injector.
  • July 30, 2026: Sanofi’s pipeline produced seven approvals across immunology, oncology, neurology, and rare diseases.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Professional Development Budget

Parental Leave

Company News

FinancialContent
Jul 24th, 2026
Scribe Therapeutics prices upsized $129M IPO at top of range

Scribe Therapeutics, a clinical-stage biotechnology company developing in vivo CRISPR technologies, has priced its upsized initial public offering at $15.00 per share, the high end of its range. The company is offering 8,580,000 shares, expecting to raise $128.7 million in gross proceeds before fees and expenses. Scribe has also granted underwriters a 30-day option to purchase up to 1,287,000 additional shares. The shares are expected to begin trading on the Nasdaq Global Market on 24 July 2026 under the ticker symbol "SCTX", with the offering closing on 27 July 2026. Additionally, Scribe has agreed to sell 500,000 shares at the same price to Sanofi in a concurrent private placement. Leerink Partners, Goldman Sachs, Guggenheim Securities, and Wells Fargo Securities are serving as joint book-running managers.

Associated Press
Jul 10th, 2026
Sanofi's Sarclisa Escena approved in US as first anticancer drug delivered via on-body injector

The US Food and Drug Administration has approved Sanofi's subcutaneous Sarclisa Escena for treating multiple myeloma, making it the first anticancer treatment administered through an on-body injector. The therapy uses Enable Injections' CirCLIQ device, which delivers the drug automatically with a retractable 30g needle. The approval was supported by the IRAKLIA phase 3 study, which demonstrated that Sarclisa Escena delivered via the on-body injector provided similar efficacy and safety compared to intravenous infusion, with significantly shorter treatment time and fewer infusion-related reactions. The study showed a 71.1% objective response rate in patients with relapsed or refractory multiple myeloma. More than 70,000 patients worldwide have been treated with Sarclisa-based regimens. The on-body injector aims to reduce physical burden on healthcare providers whilst offering patients greater convenience during treatment.

Yahoo Finance
Jul 5th, 2026
Sanofi appoints Paulo Fontoura as R&D chief to accelerate pharma pipeline transformation

Sanofi has appointed Paulo Fontoura as Executive Vice President and Global Head of Research & Development Pharma, effective 1 September. Based in Paris, Fontoura will oversee the company's innovation engine, spanning research, translational medicine, clinical development, and regulatory affairs. He succeeds Dr Houman Ashrafian, who is leaving to pursue new opportunities. Fontoura brings over 25 years of experience across academic medicine, translational science, and pharmaceutical innovation. The appointment comes as Sanofi drives an R&D transformation whilst progressing its pipeline across multiple therapeutic areas. Separately, MacroGenics confirmed it will receive $24.5 million in regulatory milestone payments from Sanofi following FDA accelerated approval of TZIELD to delay decline in endogenous insulin production in children. Sanofi is a global biopharmaceutical company focusing on immunology, rare diseases, and oncology.

Yahoo Finance
Jun 30th, 2026
3 high-yielding dividend stocks hit 52-week lows: Sanofi, AT&T, and Vici Properties

AT&T shares have fallen 17% in 2026, hitting new lows this week, amid concerns about SpaceX expanding its Starlink mobile service. The telecom stock's decline comes despite its stable business and typically reliable long-term growth prospects. Investors worry increased competition from Starlink could further limit AT&T's growth opportunities. However, some analysts believe the market may be overreacting to the threat. The company maintains strong fundamentals with steady cash flow supporting its dividend payments. AT&T's current challenges have pushed its dividend yield higher, potentially making it attractive for income-focused investors willing to overlook near-term competitive pressures. Sanofi and Vici Properties also recently hit 52-week lows whilst offering high dividend yields above 5%, presenting potential opportunities for bargain hunters seeking quality dividend stocks at reduced valuations.

Yahoo Finance
Jun 27th, 2026
Deutsche Bank cuts Sanofi price target to $107 from $113, maintains buy rating

Deutsche Bank has cut its price target on Sanofi to €95 from €100 whilst maintaining a Buy rating on the shares. The pharmaceutical company reported strong fiscal Q1 2026 results, with sales growing 13.6% at constant exchange rates and business earnings per share reaching €1.88. Sanofi's newly launched pharmaceuticals drove performance, with sales rising 49.6% to €1.2 billion, led by Ayvakit, ALTUVIIIO and Sarclisa. Dupixent sales grew 30.8% to €4.2 billion, whilst vaccine sales increased 2.1% to €1.3 billion. Research and development expenses rose 1.5% to €1.7 billion, whilst selling and general expenses climbed 11.6% to €2.3 billion, primarily reflecting recent acquisitions. Sanofi operates through three segments: Pharmaceuticals, Consumer Healthcare and Vaccines.